HER2+ CANCER TREATMENT WITH POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16

Provided herein are methods of suppressing the proliferation of HER2+ tumor cells and methods of treating HER2+ cancers in a subject with populations of placental-derived natural killer cells comprising a cleavage resistant CD16. The cells, such as CYNK cells, can be placental CD34+ cell-derived nat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	SOMANCHI, Srinivas, ROUSSEVA, Valentina, RAITMAN KHUTORSKOY, Irene, ZHANG, Xiaokui, KANG, Lin, ROTONDO, Salvatore, GLEASON, Joseph, MAHLAKÕIV, Tanel, MCCAULEY, James, HE, Shuyang, STOUT, Bhavani, HARIRI, Robert J, DIFIGLIA, Andrea, YE, Qian, GUO, Xuan, RANA, Hemlata, VAN DER TOUW, William
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Provided herein are methods of suppressing the proliferation of HER2+ tumor cells and methods of treating HER2+ cancers in a subject with populations of placental-derived natural killer cells comprising a cleavage resistant CD16. The cells, such as CYNK cells, can be placental CD34+ cell-derived natural killer (NK) cells. The present invention also provides methods of improving cell therapy by determining the presence of T cell clones reactive to the cell therapy. L'invention concerne des procédés de suppression de la prolifération de cellules tumorales HER2+ et des procédés de traitement de cancers du sein HER2+ chez un sujet avec des populations de cellules tueuses naturelles dérivées du placenta comprenant un CD16 résistant au clivage. Les cellules, telles que les cellules CYNK, peuvent être des cellules tueuses naturelles(NK) dérivées de cellules CD34+ placentaires. La présente invention concerne également des procédés d'amélioration de la thérapie cellulaire par détermination de la présence de clones de lymphocytes T réactifs à la thérapie cellulaire.